All In Biotech

Drug Trial Radar · NCT04338399

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 487 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

487

Actual

Start

Dec 12, 2020

Primary completion

Nov 2, 2025

Study completion Nov 2, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.

Conditions

  • Head and Neck Cancer

Interventions

  • Buparlisib & PaclitaxelDrug

    Investigation drug plus paclitaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Overall survival will be measured from time of randomization until death from any cause. The analysis will occur when all patients have been randomized and followed for 12 months.

Locations

162 sites in 17 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Yale University, Yale Cancer Center

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Kentucky

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • NYU Langone

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Hollings Cancer Center

    Charleston, South Carolina

  • West Cancer Center

    Germantown, Tennessee

  • Hope Cancer Center, UT Health East Texas

    Tyler, Texas

  • Fundacion Cenit para la Investigacion en Neurociencias

    Buenos Aires, Argentina

  • Centro de Investigacion Pergamino SA - Clinica Pergamino S.A.

    Buenos Aires, Argentina

  • Instituto de Investigaciones Metabólicas (IDIM) // Instituto de Investigaciones Metabólicas S.A.

    Ciudad Autonoma de Buenos Aire, Argentina

  • IONC SRL- Instituto Oncológico de Córdoba

    Córdoba, Argentina

  • Fundacion CORI para la Investigacion y Prevencion del Cáncer

    La Rioja, Argentina

  • Centro para la Atencion Integral del Paciente Oncologico - CAIPO

    San Miguel de Tucumán, Argentina

  • Princess Alexandra Hospital

    Brisbane, Australia

  • Universitair Ziekenhuis Gent UZ Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Belgium

  • Clinique CHC MontLégia

    Liège, Belgium

  • Clinique Saint-Pierre dOttignies CSPO

    Ottignies, Belgium

  • CHUM

    Montreal, Canada

  • CancerCare Manitoba

    Winnipeg, Canada

  • Beijing Tongren Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Hunan Cancer Hospital

    Changsha, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, China

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.